Likewise, the combination of TRAIL and oxaliplatin in p53 wt colon carcinoma cell lines was shown to be inefficient due to the p53-dependent up-regulation of TRAIL-R3 [51]. This evidence concerns the gene TP53 and colon carcinoma.